HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Elevated insulin-like growth factor binding protein-1 (IGFBP-1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival.

AbstractBACKGROUND: METHOD:
Data from 122 men with serum samples drawn within 3 months of starting ADT for metastatic prostate cancer was accessed retrospectively. IGF-1, IGF binding protein (BP)-1, leptin, and adiponectin levels were measured by multiplex electrochemiluminescence assays. A multivariable Cox model assessed the association of time to castration resistant prostate cancer (CRPC) and overall survival by the protein levels, adjusted for clinical variables, age and prostate specific antigen (PSA) levels at start of ADT, race, ECOG status, extent of metastases and were reported as hazard ratio (HR) with 95% confidence interval (CI).
RESULTS:
Median follow-up and overall survival were 44 and 42.2 months, respectively. ECOG performance status (≥ 1 vs. 0) was negatively associated with overall survival [H  = 2.8 (1.1-7.0), P = 0.03], and PSA nadir <0.2 was predictive of longer time to CRPC [HR = 0.3 (0.2-0.5), P < 0.0001]. The median time to CRPC by low, middle, and top IGFBP-1 tertile distribution was 20.7, 18.1, and 12.4 months, respectively, with HR for middle versus low tertile levels 3.1 (1.7-5), P = 0.0003, and for top versus low tertile levels was 2.4 (1.3-4.2), P = 0.003. The median overall survival by low, middle and top tertile IGFBP-1 level was 48.5, 46.4, and 32.8 months, respectively, with HR for top versus low tertile 2.5 (1.2-5.1), P = 0.01. There was no association with IGF-1, adiponectin and leptin.
CONCLUSION:
Elevated IGFBP-1 appears to be associated with shorter time to CRPC and lower overall survival in men with metastatic prostate cancer.
AuthorsJaya Sharma, Kathryn P Gray, Carolyn Evan, Mari Nakabayashi, Raina Fichorova, Jennifer Rider, Lorelei Mucci, Philip W Kantoff, Christopher J Sweeney
JournalThe Prostate (Prostate) Vol. 74 Issue 3 Pg. 225-34 (Feb 2014) ISSN: 1097-0045 [Electronic] United States
PMID24132762 (Publication Type: Journal Article)
Copyright© 2013 Wiley Periodicals, Inc.
Chemical References
  • Adiponectin
  • Antineoplastic Agents, Hormonal
  • Insulin-Like Growth Factor Binding Protein 1
  • Leptin
  • Prostate-Specific Antigen
Topics
  • Adiponectin (blood)
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents, Hormonal (therapeutic use)
  • Humans
  • Insulin-Like Growth Factor Binding Protein 1 (blood)
  • Leptin (blood)
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Prostate-Specific Antigen (blood)
  • Prostatic Neoplasms (blood, mortality, therapy)
  • Prostatic Neoplasms, Castration-Resistant (blood)
  • Retrospective Studies
  • Survival Rate
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: